Search results
Results from the WOW.Com Content Network
Novo Nordisk reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy.Novo announced an earnings per share beat ...
Novo Nordisk is the largest pharmaceutical company in Denmark. [14] Novo Nordisk's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe. [15] Revenue in 2023 was 33.724 billion USD.
A key priority for Novo Nordisk is to ensure attractive allocation of capital to shareholders. For 2023, the total dividend per share increased 51.6% to 9.40 kroner.
Sales of Ozempic were up 31% year over year, coming in at $4.2 billion, or over half of the $7.4 billion of total diabetes care sales. Wegovy sales, meanwhile, were up 55%, coming in at $1.7 ...
Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.
At present, Novo Nordisk is still unambiguously a stock that's worth purchasing and holding for years to come. Just keep an eye on its playing field, and on how its earnings hold up as the ...
LONDON (Reuters) -Novo Nordisk on Wednesday trimmed its full-year profit outlook after reporting weaker-than-expected quarterly sales of its popular weight-loss drug Wegovy, stirring worries among ...
The drugs, known as GLP-1s, have brought in $50 billion in revenue for Novo Nordisk year to date alone, but the high prices ($1,349 for Wegovy and $968 for Ozempic) have put them out of reach for ...